SCHEMBL73376

SCHEMBL73376

CCOC(=O)Cc1csc2c(OC)cccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.47
KDM4E B2RXH2 5/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 1/20 0.46
PKM P14618 1/20 0.45
ALDH1A1 P00352 5/20 0.43
HPGD P15428 5/20 0.43
MAPT P10636 4/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
DPP4 P27487 2/20 0.42
TDP1 Q9NUW8 2/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 2/20 0.41
POLB P06746 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5639741 0.88 L3MBTL1 (0.50) L3MBTL1KDM4ECYP1A2CYP3A4CYP2C9
SCHEMBL73600 0.82 L3MBTL1 (0.47) L3MBTL1KDM4ECYP1A2CYP3A4ALDH1A1
SCHEMBL3080403 0.82 LMNA (0.44) L3MBTL1KDM4EPKMALDH1A1HPGD
SCHEMBL72871 0.79 KMT2A (0.47) KDM4ECYP1A2CYP3A4CYP2C9PKM
SCHEMBL8941738 0.79 L3MBTL1 (0.56) L3MBTL1KDM4ECYP1A2CYP3A4CYP2C9
SCHEMBL2084214 0.79 ALDH1A1 (0.41) L3MBTL1KDM4EPKMALDH1A1HPGD
SCHEMBL1470623 0.78 DPP4 (0.38) CYP2C9PKMALDH1A1MAPTGAA
SCHEMBL14564346 0.77 PKM (0.42) L3MBTL1KDM4EPKMALDH1A1HPGD
SCHEMBL8787255 0.76 SMN1; SMN2 (0.56) L3MBTL1KDM4EPKMALDH1A1HPGD
SCHEMBL5451176 0.76 PKM (0.44) L3MBTL1KDM4EPKMALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831227-B1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS GLENMARK PHARMACEUTICALS SA (CH) 2013-06-19 EP disclosed
US-8129401-B2 Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them GLENMARK PHARMACEUTICALS S.A. (CH) 2012-03-06 US disclosed
US-20110190303-A1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS S.A. (CH) 2011-08-04 US disclosed
US-7943634-B2 Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors GLENMARK PHARMACEUTICALS S.A. (CH) 2011-05-17 US disclosed
US-20090306082-A1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS S.A. (CH) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306082-A1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PTGER4, NOX4, PDE4A L3MBTL1 4498/4885KDM4E 2531/4885CYP1A2 676/4885
US-20110190303-A1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PTGER4, NOX4, PDE4A L3MBTL1 4481/4885KDM4E 2674/4885CYP1A2 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.